- Home
- MPU vs ICU Comparison
MPU vs ICU Comparison
Compare MPU & ICU Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | MPU | ICU |
|---|---|---|
| Founded | 1989 | 2018 |
| Country | Singapore | United States |
| Employees | N/A | N/A |
| Industry | Transportation Services | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 14.6M | 15.6M |
| IPO Year | 2023 | 2021 |
Fundamental Metrics
Financial Performance| Metric | MPU | ICU |
|---|---|---|
| Price | $3.04 | $3.73 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | ★ 79.1K | 36.8K |
| Earning Date | 10-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $1,234,000.00 |
| Revenue This Year | N/A | $62.07 |
| Revenue Next Year | N/A | $46.55 |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 814.07 |
| 52 Week Low | $0.17 | $0.22 |
| 52 Week High | $3.88 | $5.38 |
Technical Indicators
Market Signals| Indicator | MPU | ICU |
|---|---|---|
| Relative Strength Index (RSI) | 68.96 | 71.82 |
| Support Level | $0.51 | $3.72 |
| Resistance Level | $3.88 | $4.25 |
| Average True Range (ATR) | 0.23 | 0.23 |
| MACD | 0.03 | 0.08 |
| Stochastic Oscillator | 65.50 | 91.52 |
Price Performance
Historical ComparisonAbout MPU Mega Matrix Corp.
Mega Matrix Inc is a holding company that offers investors an opportunity to participate in the growth of stablecoins, one of the fastest-evolving sectors in digital assets. The company generated revenue from the Membership and top-up streaming services revenue, Online advertising services, and Content licensing. Geographically, the company operates in the United States and Canada, Asia Pacific, Europe middle east and Africa, and Latin America.
About ICU SeaStar Medical Holding Corporation
SeaStar Medical Holding Corp is a medical technology company developing proprietary solutions to reduce the consequences of hyperinflammation on vital organs. It is developing and commercializing extracorporeal therapies that target the effector cells that drive systemic inflammation, causing direct tissue damage and secreting a range of pro-inflammatory cytokines that initiate and propagate imbalanced immune responses. The Company is comprised of a single reportable segment, which is its Device Segment.